Bruker Corporation (BRKR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bruker Corporation (BRKR) has a cash flow conversion efficiency ratio of 0.092x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($229.80 Million) by net assets ($2.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bruker Corporation - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Bruker Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Bruker Corporation for a breakdown of total debt and financial obligations.
Bruker Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bruker Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enel Chile SA ADR
NYSE:ENIC
|
0.098x |
|
BRF S.A
SA:BRFS3
|
0.142x |
|
Strathcona Resources Ltd.
TO:SCR
|
0.044x |
|
Flagstar Financial, Inc.
NYSE:FLG
|
0.030x |
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
0.016x |
|
LS Electric
KO:010120
|
0.019x |
|
CG Oncology, Inc. Common stock
NASDAQ:CGON
|
-0.048x |
|
Hindustan Copper Limited
NSE:HINDCOPPER
|
0.144x |
Annual Cash Flow Conversion Efficiency for Bruker Corporation (1999–2025)
The table below shows the annual cash flow conversion efficiency of Bruker Corporation from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Bruker Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.51 Billion | $134.10 Million | 0.053x | -61.41% |
| 2024-12-31 | $1.82 Billion | $251.30 Million | 0.138x | -44.11% |
| 2023-12-31 | $1.41 Billion | $350.10 Million | 0.248x | +7.01% |
| 2022-12-31 | $1.13 Billion | $262.00 Million | 0.231x | -11.08% |
| 2021-12-31 | $1.08 Billion | $282.40 Million | 0.260x | -23.88% |
| 2020-12-31 | $974.30 Million | $333.20 Million | 0.342x | +50.35% |
| 2019-12-31 | $938.20 Million | $213.40 Million | 0.227x | -14.11% |
| 2018-12-31 | $905.10 Million | $239.70 Million | 0.265x | +25.81% |
| 2017-12-31 | $733.50 Million | $154.40 Million | 0.210x | +11.54% |
| 2016-12-31 | $693.10 Million | $130.80 Million | 0.189x | -39.65% |
| 2015-12-31 | $732.90 Million | $229.20 Million | 0.313x | +111.14% |
| 2014-12-31 | $771.70 Million | $114.30 Million | 0.148x | -13.15% |
| 2013-12-31 | $850.20 Million | $145.00 Million | 0.171x | -9.08% |
| 2012-12-31 | $709.60 Million | $133.10 Million | 0.188x | +33.65% |
| 2011-12-31 | $624.90 Million | $87.70 Million | 0.140x | -52.58% |
| 2010-12-31 | $527.40 Million | $156.10 Million | 0.296x | -17.25% |
| 2009-12-31 | $418.80 Million | $149.80 Million | 0.358x | +4.63% |
| 2008-12-31 | $312.70 Million | $106.90 Million | 0.342x | +214.12% |
| 2007-12-31 | $259.20 Million | $28.21 Million | 0.109x | -44.65% |
| 2006-12-31 | $191.71 Million | $37.69 Million | 0.197x | -3.06% |
| 2005-12-31 | $208.03 Million | $42.19 Million | 0.203x | +5061.32% |
| 2004-12-31 | $217.47 Million | $-889.00K | -0.004x | +86.39% |
| 2003-12-31 | $202.55 Million | $-6.08 Million | -0.030x | +66.67% |
| 2002-12-31 | $126.38 Million | $-11.39 Million | -0.090x | -0.18% |
| 2001-12-31 | $127.55 Million | $-11.47 Million | -0.090x | -5430.38% |
| 2000-12-31 | $124.17 Million | $-202.00K | -0.002x | -100.30% |
| 1999-12-31 | $10.06 Million | $5.44 Million | 0.541x | -- |
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, ser… Read more